SOX17 and colorectal carcinoma: Similar results were depicted for APC, SHOX2 and SOX17 promoter methylation in metastatic vs. non-metastatic CRC patients (p = 0.0276, p = 0.0107 and p = 0.0242, respectively), although no differences were found for stage (Figure 2B).